Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...

HRV Pharma’s innovative “virtual manufacturing” model connects FDA-approved facilities to prevent prescription shortages and ...

Since their development and widespread adoption in the late 1980s, proton pump inhibitors (PPI) have transformed the field of gastroenterology. Their high efficacy and favorable safety profiles have ...

KARACHI: The Karachi Metropolitan Corporation (KMC) has launched a series of development projects worth over Rs700 million ...

Nicolas Joly, chief executive officer of Icade, said the deal allowed the group “to take advantage of favourable market ...

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue ...

This year featured a wealth of clinically important publications in gastroenterology, making it difficult to choose only 10 to highlight. In the end, the new guidelines and consensus statements below ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Francisco J. Rivera Rosario is a science communications editor experienced in developing all types of science content including, scientific journal articles, infographics, medical educational videos, ...